These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 32392110)

  • 41. Evolving Relevance of Neuroproteomics in Alzheimer's Disease.
    Lista S; Zetterberg H; O'Bryant SE; Blennow K; Hampel H
    Methods Mol Biol; 2017; 1598():101-115. PubMed ID: 28508359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Point-of-Care Devices Using Disease Biomarkers To Diagnose Neurodegenerative Disorders.
    Wei TY; Fu Y; Chang KH; Lin KJ; Lu YJ; Cheng CM
    Trends Biotechnol; 2018 Mar; 36(3):290-303. PubMed ID: 29242004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of MALDI-MSI in the investigation of psychiatric and neurodegenerative disorders: A review.
    Schubert KO; Weiland F; Baune BT; Hoffmann P
    Proteomics; 2016 Jun; 16(11-12):1747-58. PubMed ID: 27303929
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The potential roles of salivary biomarkers in neurodegenerative diseases.
    Jiao LL; Dong HL; Liu MM; Wu PL; Cao Y; Zhang Y; Gao FG; Zhu HY
    Neurobiol Dis; 2024 Apr; 193():106442. PubMed ID: 38382884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins.
    Butterfield DA; Palmieri EM; Castegna A
    Expert Rev Proteomics; 2016; 13(3):259-74. PubMed ID: 26837425
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances in quantitative neuroproteomics.
    Craft GE; Chen A; Nairn AC
    Methods; 2013 Jun; 61(3):186-218. PubMed ID: 23623823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multidimensional chromatography: a powerful tool for the analysis of membrane proteins in mouse brain.
    Lohaus C; Nolte A; Blüggel M; Scheer C; Klose J; Gobom J; Schüler A; Wiebringhaus T; Meyer HE; Marcus K
    J Proteome Res; 2007 Jan; 6(1):105-13. PubMed ID: 17203954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseases.
    Menon KN; Steer DL; Short M; Petratos S; Smith I; Bernard CC
    Mol Cell Proteomics; 2011 Jun; 10(6):M110.000042. PubMed ID: 21421798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proteome studies of CSF in AD patients.
    Davidsson P; Sjögren M
    Mech Ageing Dev; 2006 Feb; 127(2):133-7. PubMed ID: 16293296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proteomics of neurodegenerative diseases: analysis of human post-mortem brain.
    Li KW; Ganz AB; Smit AB
    J Neurochem; 2019 Nov; 151(4):435-445. PubMed ID: 30289976
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurofilaments as biomarkers in neurological disorders.
    Khalil M; Teunissen CE; Otto M; Piehl F; Sormani MP; Gattringer T; Barro C; Kappos L; Comabella M; Fazekas F; Petzold A; Blennow K; Zetterberg H; Kuhle J
    Nat Rev Neurol; 2018 Oct; 14(10):577-589. PubMed ID: 30171200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurodegenerative disorders of protein aggregation.
    Shastry BS
    Neurochem Int; 2003 Jul; 43(1):1-7. PubMed ID: 12605877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proteomics of Multiple Sclerosis: Inherent Issues in Defining the Pathoetiology and Identifying (Early) Biomarkers.
    Sen MK; Almuslehi MSM; Shortland PJ; Mahns DA; Coorssen JR
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery.
    Pieragostino D; Petrucci F; Del Boccio P; Mantini D; Lugaresi A; Tiberio S; Onofrj M; Gambi D; Sacchetta P; Di Ilio C; Federici G; Urbani A
    J Proteomics; 2010 Jan; 73(3):579-92. PubMed ID: 19666151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biomarker discovery and analysis platform: application to Alzheimer's disease.
    Kuzdzal S; Lopez M; Mikulskis A; Golenko E; DiCesare J; Denoyer E; Patton W; Ediger R; Sapp L; Ziegert T; Ackloo S; Wall MR; Mannion DP; della Cioppa G; Wolfe G; Bennett D; Melov S
    Biotechniques; 2005 Oct; 39(4):606-7. PubMed ID: 16235574
    [No Abstract]   [Full Text] [Related]  

  • 58. Cholesterol metabolism and homeostasis in the brain.
    Zhang J; Liu Q
    Protein Cell; 2015 Apr; 6(4):254-64. PubMed ID: 25682154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry combined with magnetic beads for detecting serum protein biomarkers in parkinson's disease.
    Li YH; Wang J; Zheng XL; Zhang YL; Li X; Yu S; He X; Chan P
    Eur Neurol; 2011; 65(2):105-11. PubMed ID: 21273779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Palmitoylation in Alzheimer's disease and other neurodegenerative diseases.
    Cho E; Park M
    Pharmacol Res; 2016 Sep; 111():133-151. PubMed ID: 27293050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.